Abstract
Background
We analysed cell-free DNA (cfDNA) in the plasma of patients with both malignant and benign breast lesions by real-time quantitative PCR to determine whether the finding may have diagnostic and prognostic implications.
Methods
Plasma samples were obtained from 33 patients with breast cancer, 32 patients with benign breast lesions and 50 healthy women as normal controls. Circulatory cfDNA was extracted from the plasma samples and quantified by real-time quantitative PCR for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene.
Results
The mean concentrations of cfDNA in the plasma samples from patients with breast cancer, patients with benign breast lesions and normal controls were 2,285, 1,368 and 1,489 genome equivalents (GE) per millilitre, respectively. The level of cfDNA in the breast cancer group was significantly higher than those in the benign lesion group and control group (P = 0.007 and 0.013, respectively). These findings were associated with malignant tumour size. The levels of the cfDNA were high in patients with lymph node involvement and distant metastasis.
Conclusions
Our results suggest that levels of cfDNA in the plasma are elevated in malignant breast cancer and correlated with tumour size. These findings could have diagnostic and prognostic value for malignant breast tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S (2003) Detection and clinical implications of early systemic tumour cell dissemination in breast cancer. Clin Cancer Res 9(17):6326–6334
Diel IJ, Solomayer EF, Bastert G (2000) Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88:3080–3088
Diel IJ (2000) Antitumour effects of bisphosphonates: first evidence and possible mechanisms. Drugs 59(3):391–399
Diel IJ, Mundy GR (2000) Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer 82(8):1381–1386
Diel IJ, Solomayer EF, Bastert G (2000) Micrometastatic cells in the bone marrow of patients with breast carcinoma]. Radiologe 40(8):681–687
Pantel K, Woelfle U (2005) Detection and molecular characterisation of disseminated tumour cells: implications for anti-cancer therapy. Biochim Biophys Acta 1756(1):53–64
Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271–278
Bauer KD, de la Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, Priddy C, Bossy B, Ludmann S, Yamamoto K, Masih AS, Espinoza FP, Harrington DS (2000) Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 6(9):3552–3559
Anker P, Stroun M (2000) Circulating DNA in plasma or serum. Medicina (B Aires) 60:699–702
Nawroz-Danish H, Eisenberger CF, Yoo GH, Wu L, Koch W, Black C, Ensley JF, Wei WZ, Sidransky D (2004) Microsatellite analysis of serum DNA in patients with head and neck cancer. Int J Cancer 111(1):96–100
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumours. Proc Natl Acad Sci USA 102(45):16368–16373
Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP (2004) Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. Clin Cancer Res 10(7):2401–2406
Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM (2003) Pretherapy quantitative measurement of circulating Epstein–Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98(2):288–291
Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS (2005) Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res 11(4):1394–1399
Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA, Ziegler A (2004) Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22(20):4157–4164
Giacona MB, Ruben GC, Iczkowski KA, Roos TB, Porter DM, Sorenson GD (1998) Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17(1):89–97
Wu TL, Zhang D, Chia JH, Tsao KH, Sun CF, Wu JT (2002) Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin Chim Acta 321(1–2):77–87
Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB (2002) Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 22(1A):421–425
Goebel G, Zitt M, Zitt M, Muller HM (2005) Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 21(3):105–120
Zhong XY, Laivuori H, Livingston JC, Ylikorkala O, Sibai BM, Holzgreve W, Hahn S (2001) Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 184(3):414–419
Zhong XY, Holzgreve W, Hahn S (2002) The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy 21(1):77–83
Zhong XY, Holzgreve W, Hahn S (2002) Cell-free fetal DNA in the maternal circulation does not stem from the transplacental passage of fetal erythroblasts. Mol Hum Reprod 8(9):864–870
Gupta AK, Holzgreve W, Huppertz B, Malek A, Schneider H, Hahn S (2004) Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated in vitro. Clin Chem 50(11):2187–2190
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61(4):1659–1665
Bergsmedh A, Szeles A, Spetz AL, Holmgren L (2002) Loss of the p21(Cip1/Waf1) cyclin kinase inhibitor results in propagation of horizontally transferred DNA. Cancer Res 62(2):575–579
Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L (2001) Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 98(11):6407–6411
Garcia-Olmo D, Garcia-Olmo DC, Ontanon J, Martinez E (2000) Horizontal transfer of DNA and the “genometastasis hypothesis”. Blood 95(2):724–725
Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D (2004) Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 19(2):575–583
Garcia-Olmo DC, Gutierrez-Gonzalez L, Ruiz-Piqueras R, Picazo MG, Garcia-Olmo D (2005) Detection of circulating tumour cells and of tumour DNA in plasma during tumour progression in rats. Cancer Lett 217(1):115–123
Acknowledgments
We thank Dr. Dorothy Huang and Professor Dennis Lo for their helpful comments and reviewing the English. We thank Vivian Kiefer for her excellent assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhong, X.Y., Ladewig, A., Schmid, S. et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet 276, 327–331 (2007). https://doi.org/10.1007/s00404-007-0345-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-007-0345-1